Oncternal Therapeutics, Inc. (ONCT) financial statements (2022 and earlier)

Company profile

Business Address 12230 EL CAMINO REAL
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments90,76597,380103,663111,211116,73721,259
Cash and cash equivalents90,76597,380103,663111,211116,73721,259
Prepaid expense    1,266 
Other undisclosed current assets2,0882,1403,9361,873 1,448
Total current assets:92,85399,520107,599113,084118,00322,707
Noncurrent Assets
Operating lease, right-of-use asset751191622044079
Other noncurrent assets657657658769766766
Total noncurrent assets:732776820973806845
TOTAL ASSETS:93,585100,296108,419114,057118,80923,552
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,3905,5433,5024,6654,1854,250
Accounts payable1,9592,7461,0091,8921,143977
Accrued liabilities3,4312,7972,4932,7733,0423,273
Other undisclosed current liabilities752772,3981,0581,6733,301
Total current liabilities:5,4655,8205,9005,7235,8587,551
Noncurrent Liabilities
Long-term debt and lease obligation   31 79
Operating lease, liability   31 79
Total noncurrent liabilities:   62 158
Total liabilities:5,4655,8205,9005,7855,8587,709
Stockholders' equity
Stockholders' equity attributable to parent88,12094,476102,519108,303112,95115,700
Common stock494949494922
Additional paid in capital202,201200,484198,897196,999195,69995,918
Accumulated deficit(114,130)(106,057)(96,427)(88,745)(82,797)(80,240)
Total stockholders' equity:88,12094,476102,519108,303112,95115,700
Other undisclosed liabilities and equity   (31) 143
TOTAL LIABILITIES AND EQUITY:93,585100,296108,419114,057118,80923,552

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
Revenues5562,1288837481,588585
Gross profit:5562,1288837481,588585
Operating expenses(8,636)(11,765)(8,573)(6,707)(4,449)(4,980)
Operating loss:(8,080)(9,637)(7,690)(5,959)(2,861)(4,395)
Nonoperating income407811307 
Investment income, nonoperating 78113 
Other nonoperating income    304 
Loss before gain (loss) on sale of properties:(8,040)(9,630)(7,682)(5,948)(2,554)(4,395)
Other undisclosed net loss(33)   (3) 
Net loss available to common stockholders, diluted:(8,073)(9,630)(7,682)(5,948)(2,557)(4,395)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
Net loss:(8,073)(9,630)(7,682)(5,948)(2,557)(4,395)
Comprehensive loss, net of tax, attributable to parent:(8,073)(9,630)(7,682)(5,948)(2,557)(4,395)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: